To include your compound in the COVID-19 Resource Center, submit it here.

Stelara meets Crohn's endpoints

Johnson & Johnson (NYSE:JNJ) said low- and high-dose Stelara ustekinumab met the primary endpoint in the Phase IIb CERTIFI trial to treat moderately to severely

Read the full 255 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE